ALNY

309.66

3.27% -10.47

시간 외 거래: 310.05 0.39 +0.13%

Alnylam Pharmaceuticals Inc (ALNY)

개요 뉴스 가격 이력 옵션 체인 Financials ALNY 왜 하락? 토론 예측

전일 마감가:

$320.13

열려 있는:

$326.09

하루 거래량:

1.50M

Relative Volume:

1.15

시가총액:

$41.32B

수익:

$3.71B

순이익/손실:

$313.75M

주가수익비율:

137.19

EPS:

2.2571

순현금흐름:

$465.38M

1주 성능:

-3.87%

1개월 성능:

-3.36%

6개월 성능:

-35.71%

1년 성능:

+32.02%

1일 변동 폭

$306.00

$326.53

1주일 범위

$306.00

$343.36

52주 변동 폭

$228.28

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

명칭

Alnylam Pharmaceuticals Inc

부문

Healthcare (1116)

산업

Biotechnology (622)

전화

(617) 551-8200

주소

675 WEST KENDALL STREET, CAMBRIDGE, MA

직원

2,500

트위터

@alnylam

다음 수익 날짜

2026-04-30

최신 SEC 제출 서류

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, ARGX, ONC

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
ALNY Alnylam Pharmaceuticals Inc	309.66	41.32B	3.71B	313.75M	465.38M	2.2571
VRTX Vertex Pharmaceuticals Inc	441.20	112.22B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	750.57	79.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	849.04	52.80B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	323.87	35.95B	5.36B	287.73M	924.18M	2.5229

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-16	다운그레이드	Jefferies	Buy → Hold
2026-01-28	재개	Barclays	Overweight
2026-01-07	재개	Oppenheimer	Outperform
2025-08-04	업그레이드	Oppenheimer	Perform → Outperform
2025-08-04	업그레이드	Wolfe Research	Underperform → Peer Perform
2025-07-30	재개	Raymond James	Outperform
2025-07-21	개시	Truist	Buy
2025-03-31	개시	Redburn Atlantic	Buy
2025-03-24	업그레이드	JP Morgan	Neutral → Overweight
2024-11-12	다운그레이드	Wolfe Research	Peer Perform → Underperform
2024-10-16	개시	Scotiabank	Sector Outperform
2024-08-16	업그레이드	Goldman	Neutral → Buy
2024-02-16	다운그레이드	Goldman	Buy → Neutral
2024-02-15	개시	Wolfe Research	Peer Perform
2023-12-08	개시	Wells Fargo	Equal Weight
2023-10-11	다운그레이드	Oppenheimer	Outperform → Perform
2023-09-29	개시	Raymond James	Outperform
2023-05-05	업그레이드	BMO Capital Markets	Market Perform → Outperform
2023-04-26	개시	SMBC Nikko	Neutral
2023-03-21	개시	Bernstein	Outperform
2023-01-18	개시	Canaccord Genuity	Buy
2022-09-09	재개	Morgan Stanley	Equal-Weight
2022-07-13	개시	Cantor Fitzgerald	Neutral
2022-06-27	다운그레이드	Guggenheim	Buy → Neutral
2022-06-07	개시	William Blair	Outperform
2022-04-25	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	개시	Citigroup	Buy
2022-02-03	업그레이드	Guggenheim	Neutral → Buy
2022-01-03	업그레이드	Piper Sandler	Neutral → Overweight
2021-11-22	업그레이드	Goldman	Neutral → Buy
2021-11-22	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	업그레이드	Oppenheimer	Perform → Outperform
2021-10-04	업그레이드	UBS	Neutral → Buy
2021-08-04	다운그레이드	Piper Sandler	Overweight → Neutral
2021-02-22	다운그레이드	Guggenheim	Buy → Neutral
2021-02-12	다운그레이드	Citigroup	Buy → Neutral
2021-02-12	재확인	H.C. Wainwright	Buy
2021-01-25	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2020-09-30	재개	Berenberg	Hold
2020-09-08	개시	Citigroup	Buy
2020-08-11	다운그레이드	Oppenheimer	Outperform → Perform
2020-05-13	개시	RBC Capital Mkts	Sector Perform
2020-05-07	다운그레이드	JP Morgan	Overweight → Neutral
2020-04-24	재개	Evercore ISI	Outperform
2020-03-19	개시	Berenberg	Buy
2019-12-19	재확인	Chardan Capital Markets	Buy
2019-11-20	개시	Oppenheimer	Outperform
2019-11-13	개시	BofA/Merrill	Buy
2019-05-23	재개	Goldman	Neutral
2019-04-12	개시	Evercore ISI	Outperform
2019-03-06	업그레이드	Evercore ISI	In-line → Outperform
2019-03-05	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	개시	UBS	Neutral
2018-10-01	개시	Cantor Fitzgerald	Overweight
2018-08-13	재확인	Stifel	Buy
2018-08-07	업그레이드	Stifel	Hold → Buy
2018-05-04	재확인	Stifel	Hold
2018-03-28	개시	Evercore ISI	In-line

모두보기

Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스

Apr 18, 2026

Alnylam Pharmaceuticals (ALNY) presents Vutrisiran ATTR-CM data at ACC.26 - MSN

Apr 18, 2026

JP Morgan Maintains Alnylam Pharmaceuticals (ALNY) Overweight Recommendation - MSN

Apr 18, 2026

GF Fund Management CO. LTD. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Apr 18, 2026

Apr 17, 2026

A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Choppy Trading And Rich P/E Multiple - Yahoo Finance

Apr 17, 2026

RNAi Technology Market to Reach USD 9.58 Billion by 2033 at 15.26% - openPR.com

Apr 17, 2026

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results - BioSpace

Apr 17, 2026

Apr 16, 2026

Alnylam (ALNY) slides 4% as valuation concerns linger after recent analyst reset - Quiver Quantitative

Apr 16, 2026

KBC Group NV Has $138.46 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Apr 16, 2026

Wells Fargo raises Alnylam (ALNY) revenue estimates for Amvuttra despite projected margin compression - MSN

Apr 16, 2026

Apr 15, 2026

Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? - Eastern Progress

Apr 15, 2026

Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - Eastern Progress

Apr 15, 2026

Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates - Eastern Progress

Apr 15, 2026

Apr 14, 2026

Did New Vutrisiran Data and FCF Breakeven Just Shift Alnylam Pharmaceuticals' (ALNY) Investment Narrative? - simplywall.st

Apr 14, 2026

Sumitomo Mitsui Trust Group Inc. Has $130.34 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Apr 14, 2026

Apr 13, 2026

Truist Financial Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $505.00 - MarketBeat

Apr 13, 2026

Whats the beta of Alnylam Pharmaceuticals Inc stockWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn

Apr 13, 2026

Massachusetts Financial Services Co. MA Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Apr 13, 2026

Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals - Yahoo Finance

Apr 13, 2026